Find company announcements below, or check out the latest news in the right side menu.
8. February 2008
In accordance with Section 28a of the Danish Securities Trading Act, Novozymes reports the following transactions under ISIN DK0010272129, Novozymes B shares under the symbol NZYM B.
5. February 2008
On January 31, 2008, Novozymes received information that ATP and ATP Invest, Kongens Vænge 8, 3400 Hillerød, Denmark reduced its holdings of Novozymes shares to 3,203,971 B shares.
31. January 2008
30. January 2008
25. January 2008
2007 was a really good year for Novozymes. Growth was the theme of the year, with sales growth higher than expected at 14%. The financial results were satisfactory, particularly in the light of high energy and raw material prices. Unfavorable exchange rate movements had a negative impact on the resu
10. December 2007
Novozymes Biologicals Holding A/S has taken up these shares, which represent approximately 98% of the common shares of Philom Bios, and will pay for these shares today by providing the depositary with sufficient funds for transmittal to the holders of these shares.
3. December 2007
In accordance with Section 28a of the Danish Securities Trading Act, Novozymes reports the following transaction under ISIN DK0010272129, Novozymes B shares under the symbol NZYM B.
30. November 2007
28. November 2007
26. November 2007
23. November 2007
1. November 2007
31. October 2007
Today Novozymes Biologicals Holding A/S, a wholly-owned subsidiary of Novozymes A/S, (“Novozymes”), has signed a pre-acquisition agreement with Philom Bios Inc. (“Philom Bios”),
25. October 2007
Satisfactory growth and earnings for Novozymes. Sales rose by 15% in the first nine months, while growth in DKK was 11%. Operating profit rose by 14% challenged by unfavorable exchange rate movements and rising raw material and energy prices.
1. October 2007
Effective from October 1, 2007 Novozymes A/S has completed the acquisition of the enzyme activities of Biocon Limited, Bangalore, India. In reference to Stock exchange announcement no.
20. September 2007
5. September 2007
28. August 2007
Novozymes announces that the Board has appointed two new Executive Vice Presidents for Novozymes’ Executive Management, namely Thomas Nagy and Thomas Videbæk.
13. August 2007
9. August 2007
Novozymes’ results for the first half of 2007 are fully in line with the outlook. Sales rose by 14%, while operating profit rose by 20% including one-off items and by 9% based on ordinary activities.
18. July 2007
Novozymes A/S (“Novozymes”) has today signed a definitive agreement under which it will acquire the enzyme activities of Biocon Limited (”Biocon”), Bangalore, India. Novozymes does not currently hold any stake in Biocon.
1. June 2007
Pursuant to the implementation of the EU Transparency Obligations Directive into Danish law, hereunder Executive Order no. 226 of 15 March 2007 on Obligations of Issuers, the following information about the total number of voting rights and the total share capital of Novozymes A/S is hereby given.
25. April 2007
Growth in the first quarter of 2007 was significantly higher than expected. Sales grewby 18%, operating profit by 15%, and net profit for the period by 30%, as a result of which Novozymes is adjusting its outlook for 2007 upwards.
25. April 2013
1. April 2013
| Copyright © 2010 Novozymes. All Rights Reserved.